$0.73
2.82% today
Nasdaq, Nov 26, 03:19 pm CET
ISIN
US68236P1075
Symbol
ONCT
Sector
Industry

Oncternal Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Oncternal Therapeutics Inc Classifications & Recommendation:

Hold
100%

Oncternal Therapeutics Inc Price Target

Target Price $2.00
Price $0.71
Potential
Number of Estimates 1
1 Analyst has issued a Oncternal Therapeutics Inc price target 2025. The average Oncternal Therapeutics Inc target price is $2.00. This is higher than the current stock price.
A rating was issued by 1 analysts: 0 Analysts recommend Oncternal Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Oncternal Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Oncternal Therapeutics Inc stock at Hold.

Sales and Margin forecast 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.79 1.92
46.98% 143.04%
Net Margin -5,032.00% -1,916.29%
50.77% 61.92%

1 Analyst has issued a sales forecast Oncternal Therapeutics Inc 2024 . The average Oncternal Therapeutics Inc sales estimate is

$1.9m
Unlock
. This is
11.11% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.9m 11.11%
Unlock
, the lowest is
$1.9m 11.11%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $790k 46.98%
2024
$1.9m 143.04%
Unlock
2025
$600k 68.75%
Unlock

1 Analyst has issued a net profit forecast Oncternal Therapeutics Inc 2024 . The average Oncternal Therapeutics Inc net profit estimate is

$-36.8m
Unlock
. This is
6.32% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-36.8m 6.32%
Unlock
, the lowest is
$-36.8m 6.32%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-39.8m 20.06%
2024
$-36.8m 7.45%
Unlock
2025
$-30.3m 17.53%
Unlock

Net Margin

2023 -5,032.00% 50.77%
2024
-1,916.29% 61.92%
Unlock
2025
-5,056.67% 163.88%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -13.43 -12.43
20.06% 7.45%
P/E negative
EV/Sales negative

1 Analysts have issued a Oncternal Therapeutics Inc forecast for earnings per share. The average Oncternal Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-12.43
Unlock
. This is
6.33% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-12.43 6.33%
Unlock
, the lowest is
$-12.43 6.33%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-13.43 20.06%
2024
$-12.43 7.45%
Unlock
2025
$-10.25 17.54%
Unlock

P/E ratio

Current -0.06 88.46%
2024
-0.06 0.00%
Unlock
2025
-0.07 16.67%
Unlock

Based on analysts' sales estimates for 2024, the Oncternal Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

-6.40
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -5.69 78.97%
2024
-6.40 12.50%
Unlock
2025
-20.48 220.00%
Unlock

P/S ratio

Current 0.97 97.10%
2024
1.09 12.51%
Unlock
2025
3.50 219.99%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today